Episode Description
2024 HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise
- Mavacamten: Class 1 recommendation for symptomatic obstructive HCM.
- Exercise: Now allows for "vigorous" activity; competitive level still limited.
- Pediatric Section: Separate guidelines with new risk-prediction tools.
- Atrial Fibrillation: Enhanced monitoring is recommended.
- Future Research: Needed on nonobstructive HCM and cardiac myosin inhibitors' long-term effects.